Early, easy, efficient and cost-effective diagnosis of Cystic Fibrosis

Nov 28, 2019

Cystic Fibrosis is one of the most frequent life threatening inherited diseases. If detected early, effective treatment can be started improving disease prognosis.

For nearly 30 years, Fujirebio has been developing tests for genetic testing of Cystic Fibrosis.

Thousands of couples and patients have been screened with the help of our INNO-LiPA CFTR  (Cystic Fibrosis Transmembrane conductance Regulator) products, improving their prognosis for this life-threatening inherited disease. 

As routine genetic CFTR testing needs to be easy, efficient and cost-effective, Fujirebio has developed INNO-LiPA CFTR iage.

It is the ideal solution for routine genetic testing in a multi-ethnic world: covering 88 of the world’s most frequent mutations using one amplification in a single run.

INNO-LiPA CFTRiage - 88 mutations in one run

This unique and patented all-in-one approach has been described in a poster presented at EuroMedLab 2019 in Barcelona, Spain.

You can download the EuroMedLab poster here or you can download the INNO-LiPA CFTR iage product brochure and the 2-page product leaflet here.

[This article was updated on January 8th, 2020]